Histone deacetylase inhibitors have been proved to be great potential for the treatment of cancer. Recently, we designed and modified a series of substituted purine hydroxamate analogs as potent HDAC inhibitors based on our previous studies. The target compounds were investigated for their in vitro HDAC inhibitory activities and anti-proliferative activities. Results indicated that these compounds
组蛋白脱乙酰基酶
抑制剂已被证明在治疗癌症方面具有巨大潜力。最近,我们根据先前的研究设计并修饰了一系列取代的
嘌呤异羟
肟酸
酯类似物,作为有效的H
DAC抑制剂。研究了目标化合物的体外H
DAC抑制活性和抗增殖活性。结果表明,这些化合物可有效抑制H
DAC,对肿瘤细胞具有明显的抗增殖活性。可能地,目标化合物4m和4n在酶抑制活性和细胞抗增殖活性测定方面均优于
SAHA。